Pharma, Devices & Research
Explore FDA-approved epinephrine devices, the pharmaceutical companies developing allergy and asthma treatments, and the cutting-edge research shaping the future of care.
These are FDA-approved epinephrine delivery devices as of 2024–2025, plus investigational products in late-stage development. Always consult your allergist about which device is right for you or your child, and carry two doses at all times.
Viatris (formerly Mylan); distributed by Pfizer
Type
Auto-injector
Doses
0.3 mg (adult) · 0.15 mg (child)
Spring-loaded auto-injector; requires training to hold correctly. Generic versions available.
FDA approved; market leader since 1987
Visit official sitekaléo
Type
Auto-injector (voice-guided)
Doses
0.3 mg · 0.15 mg · 0.1 mg (infant)
Compact, rectangular device that provides audible step-by-step voice instructions and auto-retracts needle.
FDA approved
Visit official siteAmphastar Pharmaceuticals
Type
Prefilled syringe (auto-injector)
Doses
0.3 mg · 0.15 mg
Compact design with a smaller footprint than EpiPen; needle covered before and after use.
FDA approved
Visit official siteTeva Pharmaceuticals
Type
Auto-injector (generic for EpiPen)
Doses
0.3 mg · 0.15 mg
FDA-approved generic equivalent to EpiPen; same mechanism and dose.
FDA approved
Visit official siteARS Pharmaceuticals
Type
Nasal spray
Doses
2 mg (single spray, one nostril)
Needle-free alternative; absorbed through nasal mucosa. Game-changer for needle-phobic patients. Repeat dose allowed if no improvement.
FDA approved August 2024 — first non-injectable epinephrine
Visit official siteAquestive Therapeutics
Type
Sublingual film (orally disintegrating)
Doses
In development (prodrug epinephrine film)
First orally delivered sublingual film formulation of epinephrine (AQST-109). Applied under the tongue for rapid epinephrine delivery without a needle or nasal device. Pending FDA approval; not yet available to patients.
FDA accepted NDA 2025 — investigational, not yet FDA-approved
Visit official siteAmphastar Pharmaceuticals
Type
Inhalation aerosol (OTC)
Doses
0.125 mg per inhalation
Over-the-counter epinephrine inhaler for temporary relief of mild asthma symptoms. NOT a substitute for injectable epinephrine in anaphylaxis.
FDA approved (OTC, asthma relief only)
Visit official siteWhile we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.